Close menu


Sunderland Repository records the research produced by the University of Sunderland including practice-based research and theses.

Abstract 3505: Deregulated Expression of HDAC9 in B-Cells Leads to Lymphoproliferative Disorders As Well As Germinal Center and Post-Germinal Center Derived Lymphomas.

Gil, Veronica Sylvina, Stengel, Sven, Bhagat, Govind, Howell, Louise, Catovsky, Daniel, Pasqualucci, Laura, Petrie, Kevin and Zelent, Arthur (2012) Abstract 3505: Deregulated Expression of HDAC9 in B-Cells Leads to Lymphoproliferative Disorders As Well As Germinal Center and Post-Germinal Center Derived Lymphomas. Blood, 120 (21). p. 3505. ISSN 0006-4971

Item Type: Article


Histone Deacetylase 9 (HDAC9) is a class IIa enzyme that, within the hematopoietic system, is preferentially expressed in the B-cell lineage. Previously we have observed that, compared with normal cellular counterparts, expression of HDAC9 appears deregulated in B-lymphoid tumors (Petrie et al., JBC 278: 16059, 2003 and unpublished results). To examine the role of HDAC9 in B-cell transformation we generated a mouse model that constitutively expresses human HDAC9 from early stages of B-cell development under the control of the immunoglobulin heavy chain (IgH) enhancer (Eμ). We demonstrate that from six months of age (6–12 months), Eμ-HDAC9 transgenic mice displayed splenomegaly in a statistically significant fraction of cases (3/17, 18%), which was associated with histopathologic and immunophenotypic evidence of lymphoproliferative disease (LPD) (p<0.0001). Later in life (12 to 23 months of age), 24% (19/78) of Eμ-HDAC9 mice developed a spectrum of mature clonal B-cell lymphoproliferations including monoclonal B-cell lymphocytosis (MBL, 12/78, 15%), splenic marginal zone lymphoma (SMZL, 4/78, 5%) and diffuse large B-cell lymphoma (DLBCL, 3/78, 4%). In contrast, a low background incidence of these malignancies (2%) was observed in control mice (p = 0.0008). Importantly, the HDAC9 gene is located within chromosomal region 7p21, which is a common target of frequent genomic gains in B-cell non-Hodgkin lymphoma (B-NHL) cases and B-NHL cell lines. Consistently, copy number gains in the 7p21.1 chromosomal region were found in 25/79 (32%) primary DLBCL cases analyzed (including one B-NHL patient with a copy number gain only within the 5' end of the HDAC9 gene). Mechanism underlying the role of HDAC9 in lymphomagenesis appears to involve deacetylation of both p53 (leading to deactivation of p53) and BCL6 (leading to activation of BCL6), consistent with a role of a general hypoacetylated state in B-NHL pathogenesis, which is underscored by recently identified inactivating mutations in a number of key histone acetyltransferases. In summary, aberrant expression of HDAC9 leads to the development of B-cell lymphoproliferations, including germinal center (GC) and post-GC lymphomas, showing similarities with those occurring in humans. These findings have relevant therapeutic implications in view of current attempts to use HDAC inhibitors as anti-lymphoma drugs.

Full text not available from this repository.

More Information

Uncontrolled Keywords: b-lymphocytes, germinal center of lymph node, hdac9 gene, lymphoma, lymphoproliferative disorders, diffuse large b-cell lymphoma, immunoglobulin heavy chains, splenic marginal zone b-cell lymphoma, b-cell lymphomas, cancer
Depositing User: Kevin Petrie


Item ID: 15816
Identification Number:
ISSN: 0006-4971
Official URL:

Users with ORCIDS

ORCID for Kevin Petrie: ORCID iD

Catalogue record

Date Deposited: 22 Mar 2023 15:37
Last Modified: 22 Mar 2023 15:37


Author: Kevin Petrie ORCID iD
Author: Veronica Sylvina Gil
Author: Sven Stengel
Author: Govind Bhagat
Author: Louise Howell
Author: Daniel Catovsky
Author: Laura Pasqualucci
Author: Arthur Zelent

University Divisions

Faculty of Health Sciences and Wellbeing > School of Medicine


Sciences > Biomedical Sciences

Actions (login required)

View Item View Item